Medicinal Chemistry
CSIR NET Chemical Sciences medicinal chemistry: drug targets and inhibition, logP and QSAR, metabolism and pharmacokinetics, and the major therapeutic classes.
- 4
- Topics
- 63
- Min read
- 01 Drug Targets and Molecular Basis of Drug ActionStart here CSIR NET medicinal chemistry: enzymes, receptors, ion channels and DNA as drug targets, reversible and irreversible inhibition, agonists, Ki and IC50.
- 02 Physicochemical Properties, SAR and QSAR CSIR NET medicinal chemistry: logP and logD, pKa and ionisation, Lipinski rules, pharmacophores, bioisosterism, Hammett-Hansch QSAR and ligand efficiency.
- 03 Drug Metabolism, Prodrugs and Pharmacokinetics CSIR NET medicinal chemistry: phase I and II metabolism, cytochrome P450, prodrugs and soft drugs, half-life, clearance and bioavailability.
- 04 Major Drug Classes and Their Chemistry CSIR NET medicinal chemistry: beta-lactams, sulfonamides, antivirals, anticancer agents, NSAIDs, cardiovascular and CNS drugs, and their SAR.
- Medicinal Chemistry Formula Sheet and Short Notes Revise The whole chapter on one page.
Chapter Overview
Medicinal Chemistry appears in the CSIR NET Chemical Sciences syllabus as a single line under the interdisciplinary topics: Medicinal chemistry. There are no official sub-topics, which means the examiner can ask anything that a chemist would recognise as the chemistry of drug molecules — and in practice the questions sit at the junctions this unit covers: physical organic chemistry applied to binding and inhibition, structure–activity reasoning, the organic chemistry of metabolism, and the mechanisms of the major therapeutic classes.
That makes it an unusually rewarding unit, because almost nothing in it is new. Michaelis–Menten kinetics come from Chemical Kinetics, Hammett constants from Reaction Mechanisms, partition from Analytical Chemistry, haem chemistry from Bioinorganic Chemistry, and the ring systems from Heterocyclic Compounds. Medicinal chemistry is where they are used together.
What You’ll Learn
By the end of this chapter you will be able to:
- Identify the target class of a drug and describe how it is engaged — reversible, covalent or mechanism-based inhibition, agonism or antagonism
- Convert between \( K_d \), \( K_i \), IC\(_{50}\) and \( \Delta G^\circ \), apply the Cheng–Prusoff relations, and read a Schild plot
- Compute \( \log D \) from \( \log P \) and \( pK_a \), count Lipinski violations, and reason about why lipophilicity has an optimum
- Set up and interpret a Hansch or Free–Wilson QSAR, find the optimum \( \log P \), and judge whether a fit is trustworthy
- Predict the likely sites of phase I and phase II metabolism, recognise bioactivation, and explain prodrug and soft-drug design
- Carry out standard pharmacokinetic calculations: \( t_{1/2} \), \( V_d \), clearance, AUC, bioavailability, loading dose and time to steady state
- State the target and structural logic of the major antibacterial, antiviral, anticancer, anti-inflammatory, cardiovascular and CNS classes
Prerequisites
- Enzyme kinetics and inhibition types: Enzyme Kinetics, Salt Effects and Catalysis.
- Linear free-energy relationships and \( \sigma \) constants: Determination of Reaction Pathways.
- Functional-group chemistry used in metabolism and prodrugs: Functional Group Interconversion.
- Chirality and its biological consequences: Stereogenicity, Chirality and Configuration.
- Protein structure and binding sites: Amino Acids, Peptides and Proteins.
Learning Path
graph TD
A["1. Drug Targets and Drug Action
enzymes, receptors, channels, DNA;
Ki, IC50, Schild, covalent inhibition"] --> B["2. Properties, SAR and QSAR
logP and logD, pKa, Lipinski,
pharmacophore, bioisosteres, Hansch"]
B --> C["3. Metabolism, Prodrugs and PK
phase I and II, P450, prodrugs,
half-life, clearance, bioavailability"]
C --> D["4. Major Drug Classes
antibacterial, antiviral, anticancer,
NSAID, cardiovascular, CNS"]
A --> D
D --> E["Quick Revision
one-page sheet"]
C --> ETopics in This Chapter
| # | Topic | What it covers |
|---|---|---|
| 1 | Drug Targets and Molecular Basis of Drug Action | Enzymes, receptors, ion channels and nucleic acids as targets; \( K_d \), \( K_i \), IC\(_{50}\), EC\(_{50}\) and \( \Delta G^\circ \); Cheng–Prusoff; competitive, uncompetitive and allosteric inhibition; transition-state analogues; covalent and mechanism-based inhibitors; agonists, partial agonists and antagonists; Schild analysis; selective toxicity and the therapeutic index |
| 2 | Physicochemical Properties, SAR and QSAR | \( \log P \), \( \pi \) and \( \log D \); \( pK_a \), ionisation and the pH–partition idea; Lipinski and Veber rules; SAR tactics; pharmacophores; classical and non-classical bioisosterism; the Hansch equation and optimum \( \log P \); Craig plots, Topliss tree, Free–Wilson and 3D-QSAR; ligand efficiency and LLE |
| 3 | Drug Metabolism, Prodrugs and Pharmacokinetics | ADME; phase I oxidation by cytochrome P450 and non-P450 routes; phase II conjugations and their cofactors; bioactivation and reactive metabolites; blocking metabolism; prodrugs and soft drugs; chirality in drug action; \( t_{1/2} \), \( V_d \), clearance, AUC, bioavailability, loading dose, steady state and saturated elimination |
| 4 | Major Drug Classes and Their Chemistry | β-Lactams and resistance; glycopeptides; ribosome-targeting antibiotics; quinolones; the folate pathway; antivirals and antifungals; alkylating agents, antimetabolites and antimitotics; NSAIDs and opioids; cardiovascular, gastrointestinal and CNS classes; heterocycles in drug design |
| — | Quick Revision | Every formula, target and trap from the chapter on one page |
Where each official syllabus line is covered
| Official topic line | Page |
|---|---|
| Medicinal chemistry | 1 (targets, binding and inhibition, receptor pharmacology); 2 (physicochemical properties, SAR, QSAR, drug-likeness); 3 (metabolism, prodrugs, pharmacokinetics); 4 (therapeutic classes and their structural chemistry) |
The official syllabus lists this unit as a one-line interdisciplinary topic with no sub-topics; the four pages above divide it on textbook lines, not official ones.
How CSIR NET Asks It
Chemical Sciences is marked as follows, per the NTA information bulletin for the December 2026 cycle (one paper, 3 hours, 200 marks):
| Part | Questions given | Attempt | Correct | Wrong | Maximum |
|---|---|---|---|---|---|
| B | 40 | 35 | +2 | −0.5 | 70 |
| C | 60 | 25 | +4 | −1 | 100 |
If more than the permitted number are answered in a part, only the first ones up to that number are evaluated. The bulletin gives no count of questions per syllabus line. The kinds of question this chapter supports:
- Part B: the target of a named drug or class; the type of inhibition shown by a kinetic description; the meaning of IC\(_{50}\) versus \( K_i \); \( \log D \) from \( \log P \) and \( pK_a \); counting Lipinski violations; identifying a phase I versus a phase II transformation; naming what a prodrug releases; a one-step half-life, clearance or bioavailability calculation; recognising a bioisosteric replacement.
- Part C: extracting \( K_i \) from IC\(_{50}\) with \( [\mathrm{S}] \) and \( K_M \) given; reading a Schild experiment; diagnosing covalent versus tight-binding reversible inhibition from time- and dialysis-dependence; predicting activity from a Hansch equation and a table of \( \sigma \) and \( \pi \); ranking leads by ligand efficiency; full concentration–time data worked through to \( V_d \), CL and AUC; and “which of the following statements are correct” sets on resistance mechanisms, metabolic liabilities or class SAR.
Quick Reference
| Concept | Key fact |
|---|---|
| Binding free energy | \( \Delta G^\circ = RT\ln K_d \); one log unit ≈ 5.7 kJ mol⁻¹ at 298 K |
| Cheng–Prusoff | \( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \) |
| Schild | \( r - 1 = [\mathrm{B}]/K_B \), slope 1; p\(A_2 = -\log K_B \) |
| Distribution | \( \log D = \log P - \log(1 + 10^{\Delta}) \); \( \Delta = \mathrm{pH} - \mathrm{p}K_a \) (acid), \( \mathrm{p}K_a - \mathrm{pH} \) (base) |
| Lipinski | mass ≤ 500, \( \log P \) ≤ 5, donors ≤ 5, acceptors ≤ 10 |
| Hansch | \( \log(1/C) = -k_1(\log P)^2 + k_2\log P + k_3\sigma + \cdots \); \( \log P_0 = k_2/(2k_1) \) |
| Efficiency | \( \mathrm{LE} \approx 1.37\,\mathrm{pIC}_{50}/N_{\text{heavy}} \); \( \mathrm{LLE} = \mathrm{pIC}_{50} - \log P \) |
| Metabolism | phase I functionalises (P450 monooxygenase), phase II conjugates (UDPGA, PAPS, GSH, acetyl-CoA, SAM) |
| Pharmacokinetics | \( t_{1/2} = 0.693/k \); \( \mathrm{CL} = kV_d \); \( \mathrm{AUC} = FD/\mathrm{CL} \); steady state in 4–5 half-lives |
| Selectivity | absent target, different target, different activation, different subtype |
Metal-based drugs, imaging agents and chelation therapy are treated in Metal Complexes in Medicine, and the enzyme kinetics behind inhibition in Chemical Kinetics. For the subject overview and marking, see Chemical Sciences.